Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
396 Antidiabetic agents
3969 Others
D09978 Tofogliflozin (USAN); Tofogliflozin hydrate (JAN)
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01794 SGLT2 inhibitor
D09978 Tofogliflozin
Metabolizing enzyme substrate
DG02977 CYP2C18 substrate
D09978 Tofogliflozin
DG02978 CYP4A11 substrate
D09978 Tofogliflozin
DG02979 CYP4F3 substrate
D09978 Tofogliflozin
Drug classes [BR:br08332]
Antidiabetic agent
DG01794 SGLT2 inhibitor
D09978 Tofogliflozin
DG02044 Hypoglycemic agent
D09978 Tofogliflozin
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC5
SLC5A2 (SGLT2)
D09978 Tofogliflozin (USAN) <JP>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09978
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09978
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09978